Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clues in depression: immune signals may flag who benefits from SSRIs

NCT ID NCT06337539

Knowledge-focused Sponsor: Germans Trias i Pujol Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are studying whether immune and inflammatory markers in the blood relate to mood, fatigue, and thinking symptoms in people with major depression. The trial follows 30 adults starting SSRI antidepressants and compares them with 20 healthy volunteers. Participants give blood and complete symptom scales at the start and after three months of treatment. The goal is to see whether certain immune signals predict who improves on SSRIs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SSRI antidepressants such as sertraline, citalopram, escitalopram, fluoxetine, paroxetine, and fluvoxamine
What this could lead to
If immune markers line up with who responds to SSRIs, doctors could one day use a blood test to pick the right antidepressant sooner.
What could go wrong
The study is small and observational, so it can show links but not prove cause. Immune markers may not predict response well enough to guide treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Apr 2024

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The subjects that will participate in this study will be outpatients attended in the Outpatient Psychiatry Consultations of the Hospital Universitari Germans Trias i Pujol (Badalona, Spain) clinically diagnosed with major depression and eligible to receive antidepressant treatment with SSRIs. The control group will be made up of healthy subjects, using the same inclusion and exclusion criteria except for the psychiatric diagnosis.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years * Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5). * Eligible for receiving antidepressant treatment for major depression. Exclusion Criteria: * Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study. * Who present concurrent psychotic symptoms. * Who present disorders due to alcohol or drug use, with active consumption during the last 3 months. * Pregnant women. * Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antidepressants are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder Inflammation inflammatory disease major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antidepressants Depression Immunity Inflammation

Contacts and locations

Locations

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Catalonia, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.